Recent proof-backed calls
Public preview of tracked recommendations linked to source content, observed prices, and outcomes.
ARK’s Big Ideas 2026 (Multiomics) segment outlines the investment case for “multiomics” (integrating genomics, transcriptomics, proteomics, etc.) as biology moves from single-layer measurement to multi-layer data + computation. The talk highlights downstream implications across (1) data generation (sequencing/single-cell/proteomics platforms), (2) diagnostics (earlier, cheaper, more precise testing), (3) drug development (better target ID/stratification), and (4) therapeutics (more precise, pote
Latest market-close explanation
**TXG** (10x Genomics, Inc.) moved **+1.33%** on 2026-04-13, closing at **$23.58** after a previous close of **$23.27**. Intraday range was **$22.91** to **$24.30**. Volume changed **+38.7%** versus the prior session. Recent internal coverage also touched TXG: **Big Ideas 2026: Multiomics**.
Current stance
- beneficiary via Multiomics ‘picks-and-shovels’ benefit from rising data generation and analysis demand. from https://www.youtube.com/@ARKInvest2015 (confidence 0.58)
Top authors on this ticker
Active and historical plays
Unlock full ticker monitoring
Create an account to access full ticker history, alerts, Telegram workflows, and trust-weighted live rankings across authors, plays, and market events.